JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders

Journal of Vascular Surgery

Volumn 52, Issue 1, 2010, Pages 205-207

  Owens, Christopher D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; HEPARIN; JANUS KINASE 2; WARFARIN;

ABDOMINAL PAIN; AGED; ANOREXIA; ARTICLE; BLOOD CELL COUNT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEPATOSPLENOMEGALY; HOSPITAL ADMISSION; HUMAN; LABORATORY; MALE; MESENTERIC VEIN THROMBOSIS; MUTATION; MYELOPROLIFERATIVE DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THROMBOCYTHEMIA; TUMOR VOLUME;

AGED; ANTICOAGULANTS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; JANUS KINASE 2; MALE; MESENTERIC VASCULAR OCCLUSION; MESENTERIC VEINS; POINT MUTATION; THROMBOCYTHEMIA, ESSENTIAL; TOMOGRAPHY, X-RAY COMPUTED; VENOUS THROMBOSIS; WARFARIN;

EID: 77953688037     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2010.01.097     Document Type: Article

References (9)

1. Tefferi A. JAK2 mutations in polycythemia vera-molecular mechanisms and clinical applications. N Engl J Med 356 (2007) 444-445
2. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 (2006) 2452-2466
3. Dentali F., Squizzato A., Brivio L., et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113 (2009) 5617-5623
4. Regina S., Herault O., D'Alteroche L., Binet C., and Gruel Y. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 5 (2007) 859-861
5. Colaizzo D., Amitrano L., Tiscia G.L., Scenna G., Grandone E., Guardascione M.A., et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5 (2007) 55-61
6. Pietra D., Li S., Brisci A., Passamonti F., Rumi E., Theocharides A., et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 111 (2008) 1686-1689
7. Ali F.R., Roberts L.N., Mistry H., Patel R.K., Edmondson R.A., and Arya R. Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation. J Vasc Surg 49 (2009) 211-213
8. Arellano-Rodrigo E., Alvarez-Larran A., Reverter J.C., Villamor N., Colomer D., and Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91 (2006) 169-175
9. Hexner E.O. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Curr Opin Hematol 14 (2007) 450-454